The citrus flavanone hesperetin preferentially inhibits slow-inactivating currents of a long QT syndrome type 3 syndrome Na+ channel mutation.

Julio Alvarez-Collazo Alejandro López-Requena Loipa Galán Ariel Talavera-Perez Julio L Alvarez Karel Talavera

Published in: British journal of pharmacology (2019)

Hesperetin preferentially inhibits the slow inactivation phase of INa , more markedly in the mutant R1623Q. Hesperetin could be used as a template to develop drugs against lethal cardiac arrhythmias in LQT3.

Keyphrases

case report
left ventricular
drug induced
heart failure
mass spectrometry
molecularly imprinted